The Health Resources and Services Administration posted on its website that it had approved eight drug company plans for participation in the 340B Rebate Model Pilot Program with a start date of Jan.

Drugs that will be subject to rebates in 340B next year include Bristol Myers Squibb’s Eliquis, Johnson & Johnson’s Stelara ...

On October 26, 2023, the Health Resources and Services Administration (HRSA) issued a Notice to “inform and remind” 340B Program covered entities that to be considered eligible for the 340B program, ...

Regulators on Thursday finalized a flurry of rules with sweeping implications for U.S. providers, including Medicare reimbursement rates for hospital outpatient sites and doctor’s offices and a ...

The Patient Protection and Affordable Care Act is expected to bring significant change to the healthcare industry, including the expansion of the Public Health Service Act Section 340B Program.

Lawmakers impatient with the lack of progress on a key health care issue — the long-debated need for changes to what’s known ...

Lawmakers called for more transparency about how hospitals are using 340B revenue, including audits of participating ...

Despite the rancor, there are many bipartisan opportunities for the divided 118 th Congress. Near the top of the to-do list should be reforming the well-intentioned, but poorly designed, 340B drug ...

In this podcast, Jason Reddish, Principal and Mark Ogunsusi, Associate, at Powers Pyles Sutter & Verville provide an overview of the program and the compliance requirements. They are also two of the ...

Sen. Peter Welch (D-Vt.) has introduced a bill that would ban pharmaceutical companies from restricting access to 340B drug pricing program discounts, according to a Sept. 11 press release shared with ...

According to Silverman, one-third of all hospitals in the country participate in the 340B program and get 340B discounts with that number expected to grow without an effort to tighten eligibility ...